Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Pharmaceuticals U.S. President Geno Germano: An Interview With “The Pink Sheet” DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

Exec discusses Wyeth's selling model and how the firm is planning for potential launches this year of products like Pristiq and Torisel.

You may also be interested in...



Wyeth Suggests Pristiq Could Surpass Effexor XR In Depression Market

Combined global market for major depressive disorder and vasomotor symptoms represents 35 million women, firm says during Goldman Sachs investor conference.

Wyeth Suggests Pristiq Could Surpass Effexor XR In Depression Market

Combined global market for major depressive disorder and vasomotor symptoms represents 35 million women, firm says during Goldman Sachs investor conference.

Torisel Action Date Extended To July 5

FDA will use extension to examine new tumor evaluation information submitted by Wyeth.

Related Content

Topics

UsernamePublicRestriction

Register

PS065982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel